Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,121JPY
16 Apr 2014
Price Change (% chg)

¥24 (+2.19%)
Prev Close
¥1,097
Open
¥1,110
Day's High
¥1,124
Day's Low
¥1,096
Volume
5,728,500
Avg. Vol
9,543,600
52-wk High
¥1,340
52-wk Low
¥935

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.62
Market Cap (Mil.): ¥2,506,451.00
Shares Outstanding (Mil.): 2,284.82
Dividend: 14.00
Yield (%): 2.37

Financials

  4503.T Industry Sector
P/E (TTM): 34.06 32.56 32.65
EPS (TTM): 32.21 -- --
ROI: 6.79 19.75 19.01
ROE: 7.21 20.45 19.78
Search Stocks

Aveo, Astellas end pact to develop cancer drug tivozanib

- Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

14 Feb 2014

UPDATE 1-Aveo, Astellas end pact to develop cancer drug tivozanib

Feb 14 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.

14 Feb 2014

Aveo, Astellas end pact to develop cancer drug Tivozanib

Feb 14 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug and said they would discontinue a mid-stage study testing its use in colon cancer.

14 Feb 2014

FDA warns of heart risks with Astellas stress test chemicals

- The U.S. Food and Drug Administration warned physicians on Wednesday that two chemicals used to conduct cardiovascular stress tests can cause heart attacks and death, and it suggested resuscitation equipment and trained staff be available when the tests are conducted.

20 Nov 2013

BRIEF-FDA warns of heart risks with Astellas' Lexiscan and Adenoscan

Nov 20 - US FDA: * FDA warns of rare but serious risk of heart attack and death with Astellas

20 Nov 2013

Astellas to buy back up to $306 mln worth of own shares

TOKYO, Nov 1 - Japan's Astellas Pharma Inc said on Friday it would buy back up to 5.3 million shares, or 30 billion yen ($306 million) worth of its own stock between Nov. 5 and Dec. 16.

01 Nov 2013

UPDATE 1-Medivation cancer drug improves survival in wider use trial

* Patients showed rise in overall survival and survival without cancer worsening

22 Oct 2013

Medivation, Astellas prostate cancer drug meets trial goals

Oct 22 - Medivation Inc and its Japanese partner Astellas Pharma Inc said a late-stage trial of their experimental prostate cancer drug met the main goal of improving patients' survival.

22 Oct 2013

NICE backs Medivation, Astellas prostate cancer pill

LONDON - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service.

18 Oct 2013

UK cost agency backs Medivation, Astellas prostate cancer pill

LONDON - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service.

18 Oct 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: GlobalData
£81.00
Provider: MarketLine (a Datamonitor Company)
£114.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks